Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 14, 2019 - Issue
Submit an article Journal homepage
102
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function

Marie T Borin1 Department of Clinical and Translational Pharmacology, Theravance Biopharma US, Inc., South San Francisco, CA, USAORCID Iconhttps://orcid.org/0000-0002-1561-4051
ORCID Icon,
Arthur Lo2 Department of Drug Metabolism and Pharmacokinetics, Theravance Biopharma US, Inc., South San Francisco, CA, USAORCID Iconhttps://orcid.org/0000-0001-7474-1328
ORCID Icon,
Chris N Barnes3 Department of Biostatistics, Theravance Biopharma US, Inc., South San Francisco, CA, USA
,
Srikanth Pendyala4 Department of Clinical Development, Inflammation and Immunology, Theravance Biopharma US, Inc., South San Francisco, CA, USA
&
David L Bourdet2 Department of Drug Metabolism and Pharmacokinetics, Theravance Biopharma US, Inc., South San Francisco, CA, USACorrespondence[email protected]
Pages 2305-2318 | Published online: 08 Oct 2019

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Josuel Ora, Angelo Coppola, Mario Cazzola, Luigino Calzetta & Paola Rogliani. (2020) Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease. Journal of Experimental Pharmacology 12, pages 559-574.
Read now
Sabina Antonela Antoniu, Ruxandra Rajnoveanu, Ruxandra Ulmeanu, Florin Mihaltan & Mihaela Grigore. (2020) Evaluating revefenacin as a therapeutic option for chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 21:9, pages 997-1004.
Read now
Chitra Lal & Akram Khan. (2020) Emerging Treatments for COPD: Evidence to Date on Revefenacin. COPD: Journal of Chronic Obstructive Pulmonary Disease 17:1, pages 112-119.
Read now

Articles from other publishers (2)

Christopher Hvisdas. (2021) Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease. American Journal of Health-System Pharmacy 78:13, pages 1184-1194.
Crossref
Arthur Lo, Marie T. Borin & David L. Bourdet. (2020) Population Pharmacokinetics of Revefenacin in Patients with Chronic Obstructive Pulmonary Disease. Clinical Pharmacokinetics 60:3, pages 391-401.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.